Higher-dose semaglutide reported in the STEP UP trial
Awaiting primary-source check
Results from the STEP UP trial reported greater average weight loss at a higher semaglutide dose than the currently licensed maximum. A trial result is not a licence: any change to approved dosing requires a regulatory submission and assessment first.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.